|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleeff J, Korc M, Apte M, La Vecchia C,
Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH,
et al: Pancreatic cancer. Nat Rev Dis Primers. 2:160222016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pelosi E, Castelli G and Testa U:
Pancreatic Cancer: Molecular characterization, clonal evolution and
cancer stem cells. Biomedicines. 5:52017.
|
|
4
|
Luo J, Chen XQ and Li P: The role of TGF-β
and its receptors in gastrointestinal cancers. Transl Oncol.
12:475–484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyazono K, Katsuno Y, Koinuma D, Ehata S
and Morikawa M: Intracellular and extracellular TGF-β signaling in
cancer: Some recent topics. Front Med. 12:387–411. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawamata H, Furihata T, Omotehara F, Sakai
T, Horiuchi H, Shinagawa Y, Imura J, Ohkura Y, Tachibana M, Kubota
K, et al: Identification of genes differentially expressed in a
newly isolated human metastasizing esophageal cancer cell line,
T.Tn-AT1, by cDNA microarray. Cancer Sci. 94:699–706. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iacobuzio-Donahue CA, Velculescu VE,
Wolfgang CL and Hruban RH: Genetic basis of pancreas cancer
development and progression: Insights from whole-exome and
whole-genome sequencing. Clin Cancer Res. 18:4257–4265. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Laklai H, Miroshnikova YA, Pickup MW,
Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer
DD, Mouw JK, et al: Genotype tunes pancreatic ductal adenocarcinoma
tissue tension to induce matricellular fibrosis and tumor
progression. Nat Med. 22:497–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugimoto Y, Morita R, Hikiji K, Imura G,
Ogata Y, Yasuda D, Kono A and Iguchi H: Alteration of the CDKN2A
gene in pancreatic cancers: Is it a late event in the progression
of pancreatic cancer? Int J Oncol. 13:669–676. 1998.PubMed/NCBI
|
|
14
|
Kim SH, Han SY, Azam T, Yoon DY and
Dinarello CA: Interleukin-32: A cytokine and inducer of TNFalpha.
Immunity. 22:131–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang YH, Park MY, Yoon DY, Han SR, Lee CI,
Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, et al: Dysregulation of
overexpressed IL-32α in hepatocellular carcinoma suppresses cell
growth and induces apoptosis through inactivation of NF-κB and
Bcl-2. Cancer Lett. 318:226–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang S, Chen F and Tang L: IL-32 promotes
breast cancer cell growth and invasiveness. Oncol Lett. 9:305–307.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee HJ, Liang ZL, Huang SM, Lim JS, Yoon
DY, Lee HJ and Kim JM: Overexpression of IL-32 is a novel
prognostic factor in patients with localized clear cell renal cell
carcinoma. Oncol Lett. 3:490–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sloot YJE, Smit JW, Joosten LAB and
Netea-Maier RT: Insights into the role of IL-32 in cancer. Semin
Immunol. 38:24–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishida A, Andoh A, Inatomi O and Fujiyama
Y: Interleukin-32 expression in the pancreas. J Biol Chem.
284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Wang S, Su J, Chu G, You H, Chen
Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3
signaling and reverses interleukin-6-induced epithelial-mesenchymal
transition, invasion, and metastasis in pancreatic cancer cells.
OncoTargets Ther. 9:4225–4237. 2016. View Article : Google Scholar
|
